12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adcetris brentuximab vedotin: Additional Phase II data

Additional data from a single-arm, open-label, international Phase II trial in 58 patients with relapsed or refractory ALCL showed that Adcetris led to median PFS of 14.5 months with an estimated 1-year OS rate of 70%. Patients received 1.8 mg/kg IV Adcetris every 3 weeks for up to 16 total doses. The company has an SPA from FDA for the trial. Data were presented at the...

Read the full 310 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >